
zzso poses a serious health hazard and its treatment is often zzso This review describes the present status of pharmacological treatment of obesity in zzso 

zzso treatment may include drugs that reduce food zzso drugs that increase energy expenditure and drugs that affect zzso zzso or zzso The mode of action, efficacy and safety of each approach will be briefly zzso 

All of the pharmacological possibilities have potential activities, but also serious zzso While current zzso zzso essentially uses zzso zzso drugs, severe zzso (more particularly pulmonary hypertension and zzso heart disease) have been reported, leading to the withdrawal of licensed zzso and zzso New approaches have been recently proposed, such as zzso an zzso zzso inhibitor which decreases food zzso and zzso an zzso zzso inhibitor which decreases fat zzso zzso is a chronic disease and should be treated as such with reasonable zzso zzso one-year zzso studies demonstrated that zzso zzso and zzso significantly increased body weight loss by an average of 2-4 zzso when compared to zzso and, more interestingly, multiplied by 2-3 the number of patients who succeeded in obtaining and maintaining a reduction of more than zzso of initial body zzso Interestingly, some of these compounds may also exert zzso effects on other vascular risk factors, independently of weight zzso 

Even if all zzso pharmacological approaches can be zzso they also have important limitations so that other strategies including either combined therapies or new drugs zzso are currently under zzso 

